Carisma Therapeutics Inc. (CARM)
Carisma Therapeutics Statistics
Share Statistics
Carisma Therapeutics has 41.79M shares outstanding. The number of shares has increased by 0.5% in one year.
| Shares Outstanding | 41.79M |
| Shares Change (YoY) | 0.5% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 11.51% |
| Shares Floating | 20.22M |
| Failed to Deliver (FTD) Shares | 7.84K |
| FTD / Avg. Volume | 2.59% |
Short Selling Information
The latest short interest is 484.88K, so 1.16% of the outstanding shares have been sold short.
| Short Interest | 484.88K |
| Short % of Shares Out | 1.16% |
| Short % of Float | 1.45% |
| Short Ratio (days to cover) | 2.95 |
Valuation Ratios
The PE ratio is -0.29 and the forward PE ratio is -0.35. Carisma Therapeutics's PEG ratio is 0.01.
| PE Ratio | -0.29 |
| Forward PE | -0.35 |
| PS Ratio | 0.88 |
| Forward PS | 0.9 |
| PB Ratio | -0.62 |
| P/FCF Ratio | -0.29 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Carisma Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.48, with a Debt / Equity ratio of -0.09.
| Current Ratio | 1.48 |
| Quick Ratio | 1.48 |
| Debt / Equity | -0.09 |
| Debt / EBITDA | -0.04 |
| Debt / FCF | -0.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $426.78K |
| Profits Per Employee | $-1.31M |
| Employee Count | 46 |
| Asset Turnover | 0.64 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -85.98% in the last 52 weeks. The beta is 2.79, so Carisma Therapeutics's price volatility has been higher than the market average.
| Beta | 2.79 |
| 52-Week Price Change | -85.98% |
| 50-Day Moving Average | 0.34 |
| 200-Day Moving Average | 0.72 |
| Relative Strength Index (RSI) | 40.81 |
| Average Volume (20 Days) | 303.13K |
Income Statement
In the last 12 months, Carisma Therapeutics had revenue of 19.63M and earned -60.48M in profits. Earnings per share was -1.46.
| Revenue | 19.63M |
| Gross Profit | 19.63M |
| Operating Income | -62.18M |
| Net Income | -60.48M |
| EBITDA | -58.83M |
| EBIT | -62.18M |
| Earnings Per Share (EPS) | -1.46 |
Balance Sheet
The company has 17.91M in cash and 2.48M in debt, giving a net cash position of 15.43M.
| Cash & Cash Equivalents | 17.91M |
| Total Debt | 2.48M |
| Net Cash | 15.43M |
| Retained Earnings | -305.58M |
| Total Assets | 30.46M |
| Working Capital | 7.77M |
Cash Flow
In the last 12 months, operating cash flow was -59.92M and capital expenditures -123K, giving a free cash flow of -60.04M.
| Operating Cash Flow | -59.92M |
| Capital Expenditures | -123K |
| Free Cash Flow | -60.04M |
| FCF Per Share | -1.45 |
Margins
Gross margin is 100%, with operating and profit margins of -316.72% and -308.05%.
| Gross Margin | 100% |
| Operating Margin | -316.72% |
| Pretax Margin | -308.05% |
| Profit Margin | -308.05% |
| EBITDA Margin | -299.64% |
| EBIT Margin | -316.72% |
| FCF Margin | -305.83% |
Dividends & Yields
CARM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CARM is $1, which is 334.8% higher than the current price. The consensus rating is "Hold".
| Price Target | $1 |
| Price Target Difference | 334.8% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Mar 8, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | Mar 8, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -19.74 |
| Piotroski F-Score | 3 |